GMCSF/ IL-3 Fusion Protein Human Recombinant ( PIXY321 Human )
Referencia PT_41766-2ug
embalaje : 2ug
Marca : Novatein Biosciences
Contact local distributor :
Teléfono : +1 850 650 7790
GMCSF/ IL-3 Fusion Protein Human Recombinant ( PIXY321 Human )
DescriptionGMCSF/IL3 fusion protein Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain having a Mw of 30kDa.PIXY321 is purified by proprietary chromatographic techniques.SourceEscherichia Coli.Physical
Data sheet
| Formulation | The protein was lyophilized after extensive dialysis against 10mM PBS, pH= 7.40.1 and 0.1% BSA. |
| Solubility | It is recommended to reconstitute the lyophilized PIXY321 in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. |
| Purity | Greater than 95.0% as determined by1. Analysis by RP-HPLC.2. Analysis by SDS-PAGE. |
| Description | GMCSF/IL3 fusion protein Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain having a Mw of 30kDa.PIXY321 is purified by proprietary chromatographic techniques. |
| Protein Background | Synergism of IL3 together with GMCSF causes a rapid rise in neutrophils due to GMCSF and a slower rise in platelets due to IL3 which has strong stimulated effect on hematopoietic cells.The analog of GMCSF/IL3 is PIXY321. Results indicate that PIXY321 can stimulate multilineage hematopoiesis in vivo and enhance neutrophil and platelet recovery following chemotherapy and bone marrow transplantation (BMT). These results suggest that PIXY321 elicits the biological effects of both its component cytokines and represents a novel means of delivering two independent but interactive cytokines in combination. |
| Expression host | Escherichia Coli. |
| Synonyms | PIXY321, GMCSF/ IL3. |
| Reagent Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability | Lyophilized PIXY321although stable at room temperature for 3 weeks, should be stored desiccated below -18should be stored at 4-7 days and for future use below -18 as determined by the dose-dependant stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line) is |